One-Time immune boost for ARID1A-Mutant cancers?
NCT ID NCT06824363
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether a single dose of two immunotherapy drugs (tremelimumab and durvalumab) can increase cancer-fighting immune cells inside tumors. It includes 34 people with untreated, non-metastatic stomach or esophageal cancers that have an ARID1A gene mutation. The main goal is to see if the treatment is feasible and changes the tumor's immune environment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tremelimumab and Durvalumab (two immunotherapy drugs given as a single dose)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat stomach and esophageal cancers that have a specific genetic mutation (ARID1A).
What could go wrong
This is a very early, small proof-of-principle study with only 34 people. It is designed to see if the drugs increase immune cells in the tumor, not yet to prove they shrink tumors or extend life. Immune checkpoint inhibitors can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States